Estradiol+Drospirenone — Competitive Intelligence Brief

Estradiol+Drospirenone (Estradiol+Drospirenone) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combined oral contraceptive. Area: Contraception / Gynecology.

marketed Combined oral contraceptive Estrogen receptors (ER-α, ER-β) and progesterone receptors (PR); mineralocorticoid receptor antagonism Contraception / Gynecology Small molecule

Target snapshot

Estradiol+Drospirenone (Estradiol+Drospirenone) — Brigham and Women's Hospital. Estradiol and drospirenone work together as a hormonal contraceptive by suppressing ovulation through negative feedback on the hypothalamic-pituitary-ovarian axis.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Estradiol+Drospirenone TARGET	Estradiol+Drospirenone	Brigham and Women's Hospital	marketed	Combined oral contraceptive	Estrogen receptors (ER-α, ER-β) and progesterone receptors (PR); mineralocorticoid receptor antagonism
Ethinyl Estradiol + Cyproterone acetate	Ethinyl Estradiol + Cyproterone acetate	Fundação Educacional Serra dos Órgãos	marketed	Combined oral contraceptive with anti-androgenic activity	Androgen receptor (cyproterone acetate); estrogen receptor (ethinyl estradiol); gonadotropin suppression
Ethinyl estradiol / dienogest	Ethinyl estradiol / dienogest	Helsinki University Central Hospital	marketed	Combined oral contraceptive	Estrogen receptor, progesterone receptor
OCR	OCR	Hoffmann-La Roche	marketed	Combined oral contraceptive	Estrogen receptor and progesterone receptor
Drospirenone / Estetrol	Drospirenone / Estetrol	University of Palermo	marketed	Combined oral contraceptive	Progesterone receptor, estrogen receptor
Ethinylestradiol / Dienogest	Ethinylestradiol / Dienogest	University of Palermo	marketed	Combined oral contraceptive	Estrogen receptor, progesterone receptor
Levonorgestrel and ethinylestradiol	Levonorgestrel and ethinylestradiol	IVI Madrid	marketed	Combined oral contraceptive	Progesterone receptor (levonorgestrel); estrogen receptor (ethinylestradiol)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combined oral contraceptive class)

1. University of Palermo · 3 drugs in this class
2. Teva Branded Pharmaceutical Products R&D, Inc. · 2 drugs in this class
3. Organon and Co · 2 drugs in this class
4. HRA Pharma · 1 drug in this class
5. Hansoh BioMedical R&D Company · 1 drug in this class
6. Helsinki University Central Hospital · 1 drug in this class
7. Hoffmann-La Roche · 1 drug in this class
8. IVI Madrid · 1 drug in this class
9. Leiden University Medical Center · 1 drug in this class
10. Massachusetts General Hospital · 1 drug in this class